Loading...
Loading...
TBPH| Name | Value |
|---|---|
| Revenues | 13.7M |
| Cost of Revenue | 1.3M |
| Gross Profit | 12.4M |
| Operating Expense | 28.7M |
| Operating I/L | -16.1M |
| Other Income/Expense | -1.2M |
| Interest Income | 2.5M |
| Pretax | -14.2M |
| Income Tax Expense | 1.5M |
| Net Income/Loss | -15.6M |
Theravance Biopharma, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing respiratory medicines. The company's primary revenue comes from its product portfolio, which includes YUPELRI for the treatment of chronic obstructive pulmonary disease (COPD), Izencitinib for rheumatoid arthritis and other inflammatory diseases, Ampreloxetine for neurogenic orthostatic hypotension, and other investigational medicines for respiratory and gastrointestinal disorders. Additionally, Theravance Biopharma has licensing and collaboration agreements with several pharmaceutical companies. The company generates income through the sale of its approved medicines and potential future royalties from collaborative products.
